NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD

Mary E. Rinella; Arun J. Sanyal

doi:10.1038/nrgastro.2014.232

NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD

Mary E. Rinella, Arun J. Sanyal^*

^*Corresponding author for this work

Medicine, Hepatology Division

Research output: Contribution to journal › Review article › peer-review

49 Scopus citations

Original language	English (US)
Pages (from-to)	65-66
Number of pages	2
Journal	Nature Reviews Gastroenterology and Hepatology
Volume	12
Issue number	2
DOIs	https://doi.org/10.1038/nrgastro.2014.232
State	Published - Jan 1 2015

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1038/nrgastro.2014.232

Cite this

@article{29e98a1d60664f6f872c000266149b9a,

title = "NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD",

author = "Rinella, {Mary E.} and Sanyal, {Arun J.}",

note = "Funding Information: M.E.R. has served as a consultant to AbbVie, Fibrogen, Genentech, NGM Biopharmaceuticals, Takeda and W.L. Gore and Associates. A.J.S. has stock options in Genfit. He has served as a consultant to AbbVie, Astra Zeneca, Exhalenz, Fibrogen, Genfit, Immuron, Nimbus, Nitto Denko, Salix, Takeda and Tobira. He has been an unpaid consultant to Echosens and Intercept. His institution has received grant support from Gilead, Novartis, Salix and Tobira. Funding Information: This work of the authors is supported in part by a grant from the NIH T32 DK 07150 and RO1 DK 81410 to A.J.S.",

year = "2015",

month = jan,

day = "1",

doi = "10.1038/nrgastro.2014.232",

language = "English (US)",

volume = "12",

pages = "65--66",

journal = "Nature Reviews Gastroenterology and Hepatology",

issn = "1759-5045",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - NAFLD in 2014

T2 - Genetics, diagnostics and therapeutic advances in NAFLD

AU - Rinella, Mary E.

AU - Sanyal, Arun J.

N1 - Funding Information: M.E.R. has served as a consultant to AbbVie, Fibrogen, Genentech, NGM Biopharmaceuticals, Takeda and W.L. Gore and Associates. A.J.S. has stock options in Genfit. He has served as a consultant to AbbVie, Astra Zeneca, Exhalenz, Fibrogen, Genfit, Immuron, Nimbus, Nitto Denko, Salix, Takeda and Tobira. He has been an unpaid consultant to Echosens and Intercept. His institution has received grant support from Gilead, Novartis, Salix and Tobira. Funding Information: This work of the authors is supported in part by a grant from the NIH T32 DK 07150 and RO1 DK 81410 to A.J.S.

PY - 2015/1/1

Y1 - 2015/1/1

UR - http://www.scopus.com/inward/record.url?scp=84961354544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961354544&partnerID=8YFLogxK

U2 - 10.1038/nrgastro.2014.232

DO - 10.1038/nrgastro.2014.232

M3 - Review article

C2 - 25560844

AN - SCOPUS:84961354544

SN - 1759-5045

VL - 12

SP - 65

EP - 66

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

IS - 2

ER -

NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this